October 28th 2024
“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.
September 10th 2024
Growing data point to toxins' role in fetal anomalies
February 1st 2007Atlanta-The impact of environmental toxins on male sexual development has become a topic of keen interest among pediatric urologists, who have released a growing body of data suggesting environmental links to hypospadias, cryptorchidism, and other urinary tract anomalies and diseases. At the 2006 American Academy of Pediatrics Section on Urology annual meeting, several groups presented data on the effect of in utero exposure to endocrine disrupters on the developing fetus.
Reimbursement cuts, malpractice top urologists' concerns
December 1st 2006National Report-With another year of Medicare payment cuts looming in 2007, declining reimbursement is no surprise as the number one current concern among practicing urologists, according to an exclusive survey from Urology Times and its sister publication, Contemporary Urology. Changes in reimbursement are followed closely by malpractice, office overhead, pay for performance, and increasing regulations as the top five issues that urologists are extremely or very concerned about, the first State of the Specialty survey found.
Glickman Urological Institute expands staff
November 16th 2006Three new staff members have joined the Cleveland Clinic Glickman Urological Institute: Jeffrey Palmer, MD, is the director of minimally invasive surgery, pediatric urology; Courtenay K. Moore, MD, is a specialist in female urology; and Edmund Sabanegh, MD, is head of the section of male infertility.
Bilateral varicocelectomy improves odds of pregnancy
October 1st 2006Atlanta-Men whose infertility is due to varicocele may be able to improve the likelihood of achieving impregnation by undergoing bilateral, rather than unilateral varicocelectomy, when indicated. This was the conclusion of the authors of a Canadian study presented here at the AUA annual meeting.
Performing vasectomy reversal? Use a microscope
October 1st 2006Atlanta-If you're going to perform a vasectomy reversal, use a microscope. Despite the additional time and cost involved, microsurgical vasovasostomy is superior to the loupe-assisted macroscopic technique, findings from a recent study from Korea confirm.
Surgery more accurate in finding CF-linked anomalies
October 1st 2006Atlanta-Male patients who carry any of the 25 gene mutations related to cystic fibrosis (CF) may also have anomalies of the reproductive tract, including unilateral or bilateral absence of the vas deferens or epididymal obstruction.
Obesity is linked to infertility in men
September 21st 2006Men with increased body mass index are significantly more likely to be infertile than are normal-weight men, according to research conducted at the National Institute of Environmental Health Sciences and published in Epidemiology (2006; 17:520-3).
Tandem therapies help relieve CP/CPPS symptoms
September 1st 2006Atlanta-Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has a huge impact on men's sexuality, but a combination of pelvic muscle trigger point release physiotherapy and relaxation training can go a long way toward improving sexual dysfunction in these men, said Rodney U. Anderson, MD, professor of urology, Stanford University School of Medicine, Stanford, CA.
Pollen extract improves pain in men with CP/CPPS
September 1st 2006Atlanta-Urologists can add one more alternative, plant-based medication to the list of intriguing possibilities for treating urologic disease. This one is a rye-pollen extract called Cernilton that showed promising results in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in a preliminary, placebo-controlled study from Germany.
Refined bisphosphonate schedule may offer benefit
September 1st 2006Atlanta-Bisphosphonates have already been shown to reduce loss of bone mineral density (BMD) in men undergoing androgen deprivation therapy and to reduce skeletal events and markers of bone turnover in men with metastatic prostate cancer. However, the drugs carry risks and can be expensive. That's why Dror Michaelson, MD, PhD, an assistant in medicine at Massachusetts General Hospital and instructor at Harvard Medical School, Boston, examined the effects of zoledronic acid (Zometa) in a once-annual dosing schedule that is much reduced compared with that used in past trials.
Higher paternal age influences risk of miscarriage
August 16th 2006Independent of maternal age and multiple other factors, the odds of miscarriage are significantly higher in pregnancies conceived from fathers 40 years of age or older than from fathers under 25 years of age, according to the authors of a study published in Obstetrics & Gynecology (2006; 108:369-77).
Five compounds show potential in OAB, pain syndromes
August 15th 2006Atlanta-Five new compounds-none an antimuscarinic and all in different classes-are showing potential for overactive bladder. They may also have applications in BPH, chronic prostatitis/chronic pelvic pain syndrome, and painful bladder syndrome/interstitial cystitis (PBS/IC).
Obesity doesn't influence need for secondary prostate cancer treatment
July 1st 2006Atlanta-In a recent study of nearly 6,500 men treated for localized pros-tate cancer, researchers found that being obese did not significantly affect the need for secondary treatment, nor did it result in decreased overall or disease-specific survival.
VEGF, TP1 may mark presence of sperm in men with NOA
July 1st 2006Chicago-A widely studied protein can help urologists find sperm to be used for in vitro fertilization and may even indicate another future pharmaceutical application of the substance, according to research presented here at the American Society of Andrology annual meeting here.
Agent may curb bone loss in men with prostate cancer
June 1st 2006Atlanta-Men who are being treated with androgen deprivation therapy for progressive prostate cancer face a second, less-recognized risk: osteoporosis and bone fracture. An initial report from a 2-year trial shows that weekly treatment with the oral bisphosphonate alendronate (Fosamax) can halt and even reverse the bone loss associated with androgen deprivation therapy.
FDA approves new delivery system for IV antibiotic
June 1st 2006The FDA recently approved a new delivery system for the antibioticcefoxitin, which is indicated for the treatment of urinary tractinfections, gynecologic infections (eg, pelvic inflammatorydisease), and a number of other common infections.
New biomaterial launched for treatment of Peyronie's disease
May 24th 2006Cook Urological introduced on Tuesday a new biomaterial known asSurgisis ES for the treatment of Peyronie's disease. Surgisis ES isa natural biomaterial that provides a graft that is strong, easy tohandle, easy to use, and biocompatible, the company said. Itsupports the growth of new fully vascularized host tissue in thepenis.